Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 3/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.37 |
| ▸ | PGR | P06401 | 2/20 | 0.36 |
| ▸ | AR | P10275 | 4/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23782745 | 0.79 | CYP11B1 (0.41) | EPAS1CYP11B1CYP11B2KMT2AS1PR1 | |
| SCHEMBL15287402 | 0.79 | CYP11B1 (0.41) | EPAS1CYP11B1CYP11B2KMT2AS1PR1 | |
| SCHEMBL2196969 | 0.79 | KMT2A (0.50) | EPAS1CYP11B1CYP11B2KMT2AS1PR1 | |
| SCHEMBL29529595 | 0.79 | KMT2A (0.50) | EPAS1CYP11B1CYP11B2KMT2AS1PR1 | |
| SCHEMBL31181835 | 0.79 | KMT2A (0.50) | EPAS1CYP11B1CYP11B2KMT2AS1PR1 | |
| SCHEMBL5784676 | 0.79 | KMT2A (0.50) | EPAS1CYP11B1CYP11B2KMT2AS1PR1 | |
| SCHEMBL2195961 | 0.79 | KMT2A (0.50) | EPAS1CYP11B1CYP11B2KMT2AS1PR1 | |
| SCHEMBL1413268 | 0.79 | KMT2A (0.50) | EPAS1CYP11B1CYP11B2KMT2AS1PR1 | |
| SCHEMBL9274574 | 0.78 | CYP11B1 (0.38) | EPAS1CYP11B1CYP11B2NR3C2 | |
| SCHEMBL23792923 | 0.75 | UGT2B17 (0.40) | CYP11B1CYP11B2KMT2ANR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2023-05-11 | — | — | US | disclosed |
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2023-05-11 | — | — | US | disclosed |
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2023-05-11 | — | — | US | disclosed |
| WO-2021178780-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. (US) | 2021-09-10 | — | — | WO | disclosed |
| WO-2021178780-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. (US) | 2021-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | LRRK2, PARK7, GDI2 | EPAS1 4245/4885CYP11B1 1785/4885CYP11B2 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.